Vistakon introduces 1-Day Acuvue TruEye CLs

Article

Vistakon Division of Johnson & Johnson Vision Care Inc. has announced the U.S. introduction of 1-Day Acuvue TruEye (narafilcon A) contact lenses.

 

Jacksonville, FL-Vistakon Division of Johnson & Johnson Vision Care Inc. has announced the U.S. introduction of 1-Day Acuvue TruEye (narafilcon A) contact lenses (CLs). 1-Day Acuvue TruEye is now available at some U.S. eyecare professionals’ (ECP’s) offices, with distribution expected to grow in the coming months.

The lens features Hydraclear 1 Technology, which attracts tear film to help maintain the natural ocular environment for all-day comfort, High O2 Consumption, allowing 100 percent corneal oxygen consumption at all points across minus and plus powers, and Class-1 UV-blocking, offering patients the highest level of UV protection in a contact lens, blocking approximately 96 percent of UV-A rays and greater than 99 percent of UV-B rays that reach the lens.

1-Day Acuvue TruEye (narafilcon A) will gradually replace 1-Day Acuvue TruEye (narafilcon B), which was launched in the U.S. in 2010. 

Dave Brown, Vistakon president, said: “Our aim is to quickly transition to 1-Day Acuvue TruEye (narafilcon A), and we will provide doctors with a number of tools to help smooth the conversion process for ECPs and patients. We are confident that 1-Day Acuvue TruEye (narafilcon A) will help doctors make more patients happy, and drive additional patient referrals-the key to practice growth.”

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.